Hint mode is switched on Switch off
For swift navigation between sections

Virax Biolabs Group
LEI 25490017YHIJPOXAXI93

PDF download

Choose all Reset all
Download Cancel
Organization name
Virax Biolabs Group Ltd
Country name
United Kingdom
Country of registration
Cayman Islands
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.

Awards

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
2023
I q eng
2022
I q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    25490017YHIJPOXAXI93
  • SIC
    2835 IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
  • CIK
    0001885827
Registration is required to get access.